NCT03253068 2020-05-19
Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer
Wakayama Medical University
Phase 2 Unknown
Wakayama Medical University
Stanford University
SCRI Development Innovations, LLC
Hoosier Cancer Research Network